Overall, these findings further support the potential use of drugs targeting β3-AR as a new, valuable pharmacological approach for treating preterm infants against the common adverse effects of supplemental oxygen therapy, such as bronchopulmonary dysplasia, necrotizing enterocolitis, retinopathy of prematurity, and periventricular leukomalacia. This evidence concerns the gene ADRB3 and necrotizing enterocolitis.